Abstract
Importance In patients with hematologic malignancies, the immunogenicity of the standard 2-dose mRNA-1273 coronavirus disease 19 (COVID-19) vaccination schedule is often insufficient due to underlying disease and current or recent therapy.
Objective To determine whether a 3rd mRNA-1273 vaccination raises antibody concentrations in immunocompromised hematology patients to levels obtained in healthy individuals after the standard 2-dose mRNA-1273 vaccination schedule.
Design Prospective observational cohort study.
Setting Four academic hospitals in the Netherlands.
Participants 584 evaluable immunocompromised hematology patients, all grouped in predefined cohorts spanning the spectrum of hematologic malignancies.
Exposure One additional vaccination with mRNA-1273 5 months after completion of the standard 2-dose mRNA-1273 vaccination schedule.
Main Outcomes and Measures Serum IgG antibodies to spike subunit 1 (S1) antigens prior to and 4 weeks after each vaccination, and pseudovirus neutralization of wildtype, delta and omicron variants in a subgroup of patients.
Results In immunocompromised hematology patients, a 3rd mRNA-1273 vaccination led to median S1 IgG concentrations comparable to concentrations obtained by healthy individuals after the 2-dose mRNA-1273 schedule. The rise in S1 IgG concentration after the 3rd vaccination was most pronounced in patients with a recovering immune system, but potent responses were also observed in patients with persistent immunodeficiencies. Specifically, patients with myeloid malignancies or multiple myeloma, and recipients of autologous or allogeneic hematopoietic cell transplantation (HCT) reached median S1 IgG concentrations similar to those obtained by healthy individuals after a 2-dose schedule. Patients on or shortly after rituximab therapy, CD19-directed chimeric antigen receptor T cell therapy recipients, and chronic lymphocytic leukemia patients on ibrutinib were less or unresponsive to the 3rd vaccination. In the 27 patients who received cell therapy between the 2nd and 3rd vaccination, S1 antibodies were preserved, but a 3rd mRNA-1273 vaccination did not significantly enhance S1 IgG concentrations except for multiple myeloma patients receiving autologous HCT. A 3rd vaccination significantly improved neutralization capacity per antibody.
Conclusions and Relevance The primary schedule for immunocompromised patients with hematologic malignancies should be supplemented with a delayed 3rd vaccination. B cell lymphoma patients and allogeneic HCT recipients need to be revaccinated after treatment or transplantation.
Trial Registration EudraCT 2021-001072-41
Question Can a 3rd mRNA-1273 vaccination improve COVID-19 antibody concentrations in immunocompromised hematology patients to levels similar to healthy adults after the standard 2-dose mRNA-1273 schedule?
Findings In this prospective observational cohort study that included 584 immunocompromised hematology patients, a 3rd mRNA-1273 vaccination significantly improved SARS-CoV-2 antibody concentrations to levels not significantly different from those obtained by healthy individuals after the standard 2-dose mRNA-1273 vaccination schedule. Pseudovirus neutralization capacity per antibody of wild type virus and variants of concern also significantly improved.
Meaning The primary COVID-19 vaccination schedule for immunocompromised patients with hematologic malignancies should be supplemented with a delayed 3rd vaccination.
Competing Interest Statement
Potential conflict of interest: J.C. is consultant for Novartis, received research funding from Novartis, Merus, Takeda, Genentech, BD Biosciences and royalties from Navigate and BD Biosciences. A.P.K. is consultant for Abbvie, Janssen, Astra Zeneca, BMS, Roche, LAVA, received speakers fees from Abbvie and research funding from Janssen, Abbvie, Astra Zeneca, BMS, Celgene and Roche. S.Z. received research funding from Takeda and Janssen and participated advisory boards of Takeda, Janssen, BMS/Celgene, Sanofi and Oncopeptides. T.M. is consultant for Janssen and Kite, received research funding and honoraria from BMS/Celgene, Genentech and Kite. P.M. received research funding from Astra Zenica and is consultant for GSK and BMS. I.S.N. is consultant for Janssen, BMS/Celgene, Amgen and Sanofi. None of these are conflicts of interest in the present study.
Clinical Trial
EudraCT 2021-001072-41
Funding Statement
This study was financially supported by the Dutch Research Council (NWO ZonMW, grant 10430072010009) and Amsterdam UMC.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee of the Amsterdam UMC, location Vrije University.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Potential conflict of interest: J.C. is consultant for Novartis, received research funding from Novartis, Merus, Takeda, Genentech, BD Biosciences and royalties from Navigate and BD Biosciences. A.P.K. is consultant for Abbvie, Janssen, Astra Zeneca, BMS, Roche, LAVA, received speakers fees from Abbvie and research funding from Janssen, Abbvie, Astra Zeneca, BMS, Celgene and Roche. S.Z. received research funding from Takeda and Janssen and participated advisory boards of Takeda, Janssen, BMS/Celgene, Sanofi and Oncopeptides. T.M. is consultant for Janssen and Kite, received research funding and honoraria from BMS/Celgene, Genentech and Kite. P.M. received research funding from Astra Zenica and is consultant for GSK and BMS. I.S.N. is consultant for Janssen, BMS/Celgene, Amgen and Sanofi. None of these are conflicts of interest in the present study.
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
